Orforglipron: what it is and what the evidence says
A GLP-1 receptor agonist that is NOT a peptide but a small molecule: that is why it can be taken orally without being degraded in the stomach.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilising stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Weight management, type 2 diabetes.
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
The first NON-peptide GLP-1 receptor agonist that is active orally. The evidence base is broad: phase 2 in obesity and type 2 diabetes (2023), phase 3 ATTAIN-2, phase 3b ATTAIN-MAINTAIN on weight maintenance, and a pooled analysis of hepatic safety.
The limitation that matters most
Being oral, it demands strict dosing conditions and carries its own interactions; gastrointestinal effects remain the main reason for discontinuation and, given how recent its approval is, there are still no long-term cardiovascular safety data.
Regulatory status
Approved by the FDA in 2026 for obesity. Check its current status with the EMA and in Mexico.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Prescription medicine, approved very recently. It demands strict dosing conditions.
Talk to a doctor first if there is any history of pancreatitis, medullary thyroid cancer or slow gastric emptying, or if glucose-lowering drugs are already in the picture.
What this page cannot give you
A reference page can take you this far. You know what Orforglipron is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a diploma with a verifiable folio, a record to track how you progress, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesityhuman N Engl J Med · 2023 · PMID 37351564 →
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 studyhuman Lancet · 2023 · PMID 37369232 →
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialhuman Lancet · 2026 · PMID 41275875 →
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trialhuman Nat Med · 2026 · PMID 42120723 →
- Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials Diabetes Obes Metab · 2026 · PMID 42338042 →
- Orforglipron: First Approvalreview Drugs · 2026 · PMID 42479349 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Orforglipron or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Orforglipron?
A GLP-1 receptor agonist that is NOT a peptide but a small molecule: that is why it can be taken orally without being degraded in the stomach. It is studied within the area of metabolic.
Is there human evidence for Orforglipron?
The first NON-peptide GLP-1 receptor agonist that is active orally. The evidence base is broad: phase 2 in obesity and type 2 diabetes (2023), phase 3 ATTAIN-2, phase 3b ATTAIN-MAINTAIN on weight maintenance, and a pooled analysis of hepatic safety.
Is it approved by any health agency?
Approved by the FDA in 2026 for obesity. Check its current status with the EMA and in Mexico.
What is the dose of Orforglipron?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Orforglipron is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.